Proton pump inhibitors in IPF: Beyond mere suppression of gastric acidity

QJM: An International Journal of Medicine

Volumn 109, Issue 9, 2016, Pages 577-579

  Ghebre, Y ^a   Raghu, G ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BILIRUBIN; CARBON MONOXIDE; CELL ADHESION MOLECULE; COLLAGEN; DIMETHYLARGININASE; FERRITIN; FIBRONECTIN; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTEGRIN; INTERLEUKIN DERIVATIVE; MATRIX METALLOPROTEINASE; N(G),N(G) DIMETHYLARGININE; PROTON PUMP INHIBITOR; SURFACTANT PROTEIN C; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR;

APOPTOSIS; CAPILLARY ENDOTHELIAL CELL; FIBROSING ALVEOLITIS; HUMAN; LUNG FIBROBLAST; LUNG FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH PH; CHEMISTRY; GASTROINTESTINAL DISEASES; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

GASTROINTESTINAL DISEASES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; RESEARCH DESIGN;

EID: 84988891239     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcw115     Document Type: Review

References (20)

1. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129:794-800.
2. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:1390-4.
3. Lee JCH, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, et al. for the IPFnet Investigators. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013; 1:369-76.
4. Ghebremariam YT, Cooke JP, Gerhart W, Griego C, Brower JB, Doyle-Eisele M, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med 2015; 13:249.
5. Levin TR, Sperling RM, McQuaid KR. Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux. Am J Gastroenterol 1998; 93:1060-3.
6. Littner MR, Leung FW, Ballard ED, 2nd, Huang B, Samra NK. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 2005; 128:1128-35.
7. Sasaki T, Nakayama K, Yasuda H, Yoshida M, Asamura T, Ohrui T, et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc 2009; 57:1453-7.
8. Sasaki T, Nakayama K, Yasuda H, Yamaya M. A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD. Ther Adv Respir Dis 2011; 5:91-103.
9. Ghebremariam YT, Le Pendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013; 128:845-53.
10. Ghebre YT, Raghu G. Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med 2016; 193:1345-52.
11. Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, Domschke W, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 2006; 345:1014-21.
12. Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophilendothelial cell interactions. Aliment Pharmacol Ther 2000; 14:74-81.
13. Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, Akagiri S, et al. Lansoprazole, a proton pump inhibitor, mediates antiinflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein J Pharmacol Exp Ther 2009; 331:255-64.
14. Kedika RR, Souza RF, Spechler SJ. Potential antiinflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 2009; 54:2312-7.
15. Linden PA, Gilbert RJ, Yeap BY, Boyle K, Deykin A, Jaklitsch MT, et al. Laparoscopic fundoplication in patients with endstage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006; 131:438-46.
16. Dallemagne B, Weerts J, Markiewicz S, Dewandre JM, Wahlen C, Monami B, et al. Clinical results of laparoscopic fundoplication at ten years after surgery. Surg Endosc 2006; 20:159-65.
17. Hoppo T, Jarido V, Pennathur A, Morrell M, Crespo M, Shigemura N, et al. Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and endstage lung disease before and after lung transplantation. Arch Surg 2011; 146:1041-7.
18. Bathoorn E, Daly P, Gaiser B, Sternad K, Poland C, Macnee W, et al. Cytotoxicity and induction of inflammation by pepsin in acid in bronchial epithelial cells. Int J Inflam 2011; 2011:569416.
19. Lee HJ, Han YM, Kim EH, Kim YJ, Hahm KB. A possible involvement of Nrf2-mediated heme oxygenase-1 up-regulation in protective effect of the proton pump inhibitor pantoprazole against indomethacin-induced gastric damage in rats. BMC Gastroenterology 2012; 12:143.
20. Pullamsetti SS, Savai R, Dumitrascu R, Dahal BK, Wilhelm J, Konigshoff M, et al. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci Transl Med 2011; 3:87ra53.